Biotech Stocks Presenting Opportunity | Synergy Pharmaceuticals Inc (SGYP) | MannKind Corporation (MNKD) | Gilead Sciences (GILD) | BioMarin Pharmaceutical (BMRN)

0

Looking into the biotech market today, we’re seeing a sea of red. However, every time we have a bad day, we start to see great opportunities; and that’s no different today. I’ve dug up a few stocks in biotech that I believe to be great opportunities. Here they are…

Synergy Pharmaceuticals Is Pulling Back, But Likely To Grow!

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

After releasing overwhelmingly positive data about their most recent gastrointestinal study, Synergy Pharmaceuticals stock climbed both Wednesday and Thursday; more than doubling in price since Tuesday’s close. However, the story seems to be a bit different today. Currently (11:08), SGYP is trading at $9.05 per share after a loss of 1.31% so far today. However, I’m not concerned about today’s declines. In all reality, this is natural market movement and I’m expecting to see long term gains. I wrote an in-depth post earlier today about why I believe we’ll see gains from the stock moving forward. For more information, click here!

MannKind Corporation Stock Is Getting Ready For A Catalyst!

MannKind Corporation (NASDAQ: MNKD)

MannKind has been a very interesting stock to watch recently. After Goldman Sachs downgraded the stock early in the year, MNKD nosedived. However, a few weeks ago, Jefferies released data from their recent survey into Afrezza. The data showed that around 65% of endocrinologists not only know about Afrezza, but plan on using it in the future. As a result, MNKD started to climb. Nonetheless, today, the stock is down; currently (11:15) trading at $5.93 per share after a loss of 0.50% so far today. However, this is one to watch closely. That’s because Afrezza, MannKind’s signature product has been in pre-launch phase. However, we are only weeks away from the Direct-to-Consumer campaign; which will most likely send Afrezza sales up and MNKD is likely to follow.

Gilead Sciences Stock Is Down | Not For Long!

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead Sciences is a stock that I’ve followed for quite some time now. As the leader in the HIV and HCV markets, GILD is an incredibly strong company in biotech. While we got a bit of a scare from AbbVie Inc (NYSE: ABBV); in the long run, the GILD treatment is far superior to the treatment provided by ABBV and investors are noticing. So, the stock continues a bullish trend. This is one that’s likely to grow long term. With that said, today’s pull-back is likely a great opportunity.

BioMarin Pharmaceutical Stock Declines After Recent Gains

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)

Finally, we have BioMarin. Earlier this week, BioMarin stock went on a massive climb after announcing data from a recent study looking into an experimental drug that’s designed to restore a normal growth rate in children with the most common form of dwarfism. The data was overwhelmingly positive; however, the stock is declining today. Nonetheless, this is another story of a correction that will likely lead to big gains; like SGYP. So, today’s declines are looking like another great opportunity!

Do You Know Of Any Others?

Are you tracking great opportunities in biotech? If so, let us know what they are in the comments below!

Image Credit

LEAVE A REPLY

Please enter your comment!
Please enter your name here